Clinical Trials | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Comprehensive clinical development programs being initiated for each investigational candidate
Innovent will supply sintilimab for the collaborated clinical trial
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Subscribe To Our Newsletter & Stay Updated
